At a glance
ClinicalIndex Comparison RecordPhase 1Withdrawn· 0 enrolled
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Ovarian Failure
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 15, 2021·Updated Apr 6, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Ovarian Failure. Withdrawn before enrollment, across 1 site.
Signals
Trial was withdrawn before enrollment
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Ovarian Failure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Failure
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1WithdrawnFinished
20222023202420252026
First PostedDec 2021
Enrollment StartApr 2025
Primary CompletionApr 2025
TodayJul 2026
First PostedDec 15, 2021
Enrollment StartApr 3, 2025
Primary CompletionApr 3, 2025
TodayJul 1, 2026
Enrollment to primary: 0 daysPosted 4.5 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells